<?xml version='1.0' encoding='UTF-8'?>

      <!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 9.6.7556.35618 -->
      <!-- Based on: iXBRL 1.1 -->
      <!-- Created on: 11/17/2020 10:03:20 PM -->
      <!-- iXBRL Library version: 1.0.7556.35625 -->
      <!-- iXBRL Service Job ID: 2255f780-ad0f-4647-b22c-f8f3415dd084 -->

  <html xmlns:dei="http://xbrl.sec.gov/dei/2020-01-31" xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:krbp="http://www.kiromic.com/20201117" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance"><head><meta http-equiv="content-type" content="text/html" /><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric contextRef="Duration_11_17_2020_To_11_17_2020_PYQN3xYZu0-Qb1NMusgcbA" name="dei:EntityCentralIndexKey" id="Tc_9UHnSye9Z0iHjTDBfY23sg_2_1">0001792581</ix:nonNumeric><ix:nonNumeric contextRef="Duration_11_17_2020_To_11_17_2020_PYQN3xYZu0-Qb1NMusgcbA" name="dei:AmendmentFlag" id="Tc_GU-yB4JjsEKkZqfPzk3I1Q_3_1">false</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="krbp-20201117.xsd" xlink:type="simple"></link:schemaRef></ix:references><ix:resources><xbrli:context id="Duration_11_17_2020_To_11_17_2020_PYQN3xYZu0-Qb1NMusgcbA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001792581</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-17</xbrli:startDate><xbrli:endDate>2020-11-17</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="padding-top:1.0px;border-top:3.0pt solid #000000;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-top:1pt;text-align:center;text-indent:0pt;border-top:1.0pt solid #000000;margin:0pt;"><span style="font-size:17pt;font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_b89aa355_6c0a_4404_bf4f_8a0a5f32459b"></a></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-size:17pt;font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-size:17pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Washington, DC 20549</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:17pt;text-align:center;text-indent:0pt;margin:0pt 0pt 5pt 0pt;"><b style="font-weight:bold;">FORM&#160;</b><ix:nonNumeric contextRef="Duration_11_17_2020_To_11_17_2020_PYQN3xYZu0-Qb1NMusgcbA" name="dei:DocumentType" id="Narr_isWJVxhPfUahRKM_hQOyfw"><b style="font-weight:bold;">8-K</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">CURRENT REPORT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 10pt 0pt;"><b style="font-weight:bold;">Pursuant to Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 10pt 0pt;">Date of Report (Date of earliest event reported): <ix:nonNumeric contextRef="Duration_11_17_2020_To_11_17_2020_PYQN3xYZu0-Qb1NMusgcbA" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate" id="Narr_QZlsnYcjSES4PAmkTr7n8A">November&#160;17, 2020</ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:17pt;text-align:center;text-indent:0pt;margin:0pt;"> <ix:nonNumeric contextRef="Duration_11_17_2020_To_11_17_2020_PYQN3xYZu0-Qb1NMusgcbA" name="dei:EntityRegistrantName" id="Narr_aP-zH8Rk806bpjsiAW7uUg"><b style="font-weight:bold;">KIROMIC BIOPHARMA,&#160;INC.</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 6pt 0pt;">(Exact name of registrant as specified in its charter)</p><a id="_dacdc595_dbc8_4453_b10f_825f8114dd21"></a><a id="Tc__JI8MEGXVUWLsRlPdoi68g_2_0"></a><a id="Tc__qF8070SMkOi4aNvU7T5mQ_2_2"></a><a id="Tc_r1_e-Hiafk6UmTPVS0W35g_2_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:37.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:2.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:27.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:29.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:37.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_11_17_2020_To_11_17_2020_PYQN3xYZu0-Qb1NMusgcbA" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode" id="Tc_D0MEDcHl0UeFh5DuRW2Nzw_1_0"><b style="font-weight:bold;">Delaware</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:top;width:27.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_11_17_2020_To_11_17_2020_PYQN3xYZu0-Qb1NMusgcbA" name="dei:EntityFileNumber" id="Tc_tyf1Exy8UkmUyFqHtMEZxw_1_2"><b style="font-weight:bold;">001-39619</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:top;width:29.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_11_17_2020_To_11_17_2020_PYQN3xYZu0-Qb1NMusgcbA" name="dei:EntityTaxIdentificationNumber" id="Tc_44koBdmbv0uecLRKc_C1Gg_1_4"><b style="font-weight:bold;">46-4762913</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:37.1%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;">(State or other jurisdiction <br />of incorporation)</p></td><td style="vertical-align:top;width:2.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:27.7%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;">(Commission <br />File Number)</p></td><td style="vertical-align:top;width:2.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:29.51%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;">(IRS Employer <br />Identification No.)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_11_17_2020_To_11_17_2020_PYQN3xYZu0-Qb1NMusgcbA" name="dei:EntityAddressAddressLine1" id="Narr__0leIintxE2rLzGwJhFm8g"><b style="font-weight:bold;">7707 Fannin, Suite&#160;140</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_11_17_2020_To_11_17_2020_PYQN3xYZu0-Qb1NMusgcbA" name="dei:EntityAddressCityOrTown" id="Narr_dZehr5JkL0OvN9x_HmN9cA"><b style="font-weight:bold;">Houston</b></ix:nonNumeric><b style="font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_11_17_2020_To_11_17_2020_PYQN3xYZu0-Qb1NMusgcbA" name="dei:EntityAddressStateOrProvince" id="Narr_EXtqpnmYckuWF8pP0qMHPQ"><b style="font-weight:bold;">TX</b></ix:nonNumeric><b style="font-weight:bold;">, </b><ix:nonNumeric contextRef="Duration_11_17_2020_To_11_17_2020_PYQN3xYZu0-Qb1NMusgcbA" name="dei:EntityAddressPostalZipCode" id="Narr_etEU91RKpU2zee1s2vSJlA"><b style="font-weight:bold;">77054</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:30.45pt;margin:0pt 0pt 12pt 0pt;">(Address of principal executive offices) (Zip Code) </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:30.45pt;margin:0pt 0pt 12pt 0pt;">Registrant&#8217;s telephone number, including area code <b style="font-weight:bold;">(</b><ix:nonNumeric contextRef="Duration_11_17_2020_To_11_17_2020_PYQN3xYZu0-Qb1NMusgcbA" name="dei:CityAreaCode" id="Narr_cTCa_g1350qAqHgL5Eqzzg"><b style="font-weight:bold;">832</b></ix:nonNumeric><b style="font-weight:bold;">) </b><ix:nonNumeric contextRef="Duration_11_17_2020_To_11_17_2020_PYQN3xYZu0-Qb1NMusgcbA" name="dei:LocalPhoneNumber" id="Narr_CYbSdoDonE6W78Z9kBwa9g"><b style="font-weight:bold;">968-4888</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 5.95pt;">Check the appropriate box below if the Form&#160;8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</p><table style="border-collapse:collapse;border:0;"><tr><td style="width:5.9pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:10.65pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><ix:nonNumeric contextRef="Duration_11_17_2020_To_11_17_2020_PYQN3xYZu0-Qb1NMusgcbA" format="ixt-sec:boolballotbox" name="dei:WrittenCommunications" id="Narr_qcRJsJ9Y_kmjBoWcluDPgw"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">Written communications pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425)</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:5.9pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:10.65pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><ix:nonNumeric contextRef="Duration_11_17_2020_To_11_17_2020_PYQN3xYZu0-Qb1NMusgcbA" format="ixt-sec:boolballotbox" name="dei:SolicitingMaterial" id="Narr_Xm864nib5kqmHRPIa8MwjQ"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR 240.14a-12)</p></td></tr></table><table style="border-collapse:collapse;border:0;"><tr><td style="width:5.9pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:10.65pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;"><ix:nonNumeric contextRef="Duration_11_17_2020_To_11_17_2020_PYQN3xYZu0-Qb1NMusgcbA" format="ixt-sec:boolballotbox" name="dei:PreCommencementTenderOffer" id="Narr_FWB-fp2x7E-lf9w2qsAEeQ"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;">Pre-commencement communications pursuant to Rule&#160;14d-2(b)&#160;under the Exchange Act (17 CFR 240.14d-2(b))</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:16.95pt;text-indent:-16.95pt;margin:0pt 0pt 10pt 5.94pt;"><ix:nonNumeric contextRef="Duration_11_17_2020_To_11_17_2020_PYQN3xYZu0-Qb1NMusgcbA" format="ixt-sec:boolballotbox" name="dei:PreCommencementIssuerTenderOffer" id="Narr_BkIJjFt1ckO_MCP9IWn07g"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric><span style="font-family:'Arial','Helvetica','sans-serif';">&#160;</span>Pre-commencement communications pursuant to Rule&#160;13e-4(c)&#160;under the Exchange Act (17 CFR 240.13e-4(c))</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:16.95pt;text-indent:-16.95pt;margin:0pt 0pt 10pt 5.94pt;">Securities registered pursuant to Section&#160;12(b)&#160;of the Act:</p><a id="_194955e5_144b_4d8e_81e9_ee731d411109"></a><a id="Tc_Ny-b3DI3pkaohsix_ttBYg_1_0"></a><a id="Tc_SgFpZ9djZkuu7bcF1EGl-w_1_2"></a><a id="Tc_QD4_9AdwOEqEl76sMHxdNw_1_4"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:31.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:3.18%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:20.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:3.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:top;width:41.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:top;width:31.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Title of Each Class</b></p></td><td style="vertical-align:top;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:top;width:20.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Trading Symbol(s)</b></p></td><td style="vertical-align:top;width:3.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:top;width:41.35%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><b style="font-weight:bold;">Name of Each Exchange on Which Registered</b></p></td></tr><tr><td style="vertical-align:top;width:31.51%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_11_17_2020_To_11_17_2020_PYQN3xYZu0-Qb1NMusgcbA" name="dei:Security12bTitle" id="Tc_eKOT6JDpR0OZBv5gwh61hQ_2_0">Common Stock, $0.001 par value</ix:nonNumeric></p></td><td style="vertical-align:top;width:3.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:20.03%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_11_17_2020_To_11_17_2020_PYQN3xYZu0-Qb1NMusgcbA" name="dei:TradingSymbol" id="Tc_dbVAzo7_OEemGyv3Uwc-yw_2_2">KRBP</ix:nonNumeric></p></td><td style="vertical-align:top;width:3.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="font-weight:bold;margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:41.35%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_11_17_2020_To_11_17_2020_PYQN3xYZu0-Qb1NMusgcbA" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName" id="Tc_mwd8mL3YQECn7vcXbzLEAw_2_4">The Nasdaq Stock Market LLC</ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 10pt 22.9pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule&#160;405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule&#160;12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:22.9pt;margin:0pt 0pt 9pt 0pt;">Emerging growth company <ix:nonNumeric contextRef="Duration_11_17_2020_To_11_17_2020_PYQN3xYZu0-Qb1NMusgcbA" format="ixt-sec:boolballotbox" name="dei:EntityEmergingGrowthCompany" id="Narr_1g5AIAcKW0eV8bV7DN64bQ"><span style="font-family:'Segoe UI Symbol';">&#9746;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 0pt 22.9pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act. <ix:nonNumeric contextRef="Duration_11_17_2020_To_11_17_2020_PYQN3xYZu0-Qb1NMusgcbA" format="ixt-sec:boolballotbox" name="dei:EntityExTransitionPeriod" id="Narr_W_2tg9o2v0GOmLuBaWi6yA"><span style="font-family:'Segoe UI Symbol';">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 0pt 22.9pt;"><span style="font-family:'Segoe UI Symbol';margin-bottom:12pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><div style="margin-left:22.9pt;padding-bottom:1.0px;border-bottom:3.0pt solid #000000;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;text-indent:0pt;border-bottom:1.0pt solid #000000;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><a id="_fb73d1c7_0749_4a5e_8c13_5e40f8b89636"></a></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="display:inline-block;text-indent:0pt;width:72pt;"><b style="color:#000000;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;text-align:left;">Item&#160;8.01</b></span>Other Events.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In an effort to allocate responsibilities more evenly amongst our independent directors, our Board of Directors (the &#8220;<b style="font-weight:bold;">Board</b>&#8221;) approved a restructuring of the committees, effective as of November&#160;12, 2020 (the &#8220;<b style="font-weight:bold;">Committee Restructuring</b>&#8221;). As of the date hereof, the Board has the following three committees: audit committee (the &#8220;<b style="font-weight:bold;">Audit Committee</b>&#8221;), compensation committee (the &#8220;<b style="font-weight:bold;">Compensation Committee</b>&#8221;) and nominating and corporate governance committee (the &#8220;<b style="font-weight:bold;">Nominating Committee</b>&#8221;). The membership of the committees after the Committee Restructuring are described below. Each of our committees operates under a written charter (the &#8220;<b style="font-weight:bold;">Committee Charters</b>&#8221;) adopted by the Board.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In connection with the Committee Restructuring, the Board appointed members to each such committee. The membership of these three standing committees of the Board is as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:25.38%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">Audit Committee</b></p></td><td style="vertical-align:middle;width:3.69%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;"><span style="font-size:9.5pt;">&#160;&#160;&#160;</span></p></td><td style="vertical-align:middle;width:35.58%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">Compensation Committee</b></p></td><td style="vertical-align:middle;width:3.69%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;"><span style="font-size:9.5pt;">&#160;&#160;&#160;</span></p></td><td style="vertical-align:middle;width:31.62%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;"><b style="font-size:9.5pt;font-weight:bold;">Nominating Committee</b></p></td></tr><tr><td style="vertical-align:middle;width:25.38%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;"><span style="font-size:9.5pt;">&#160;</span></p></td><td style="vertical-align:middle;width:3.69%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;"><span style="font-size:9.5pt;">&#160;</span></p></td><td style="vertical-align:middle;width:35.58%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;"><span style="font-size:9.5pt;">&#160;</span></p></td><td style="vertical-align:middle;width:3.69%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;"><span style="font-size:9.5pt;">&#160;</span></p></td><td style="vertical-align:middle;width:31.62%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;"><span style="font-size:9.5pt;">&#160;</span></p></td></tr><tr><td style="vertical-align:middle;width:25.38%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><span style="font-size:9.5pt;">Pietro Bersani (Chairperson)</span></p></td><td style="vertical-align:middle;width:3.69%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;"><span style="font-size:9.5pt;">&#160;</span></p></td><td style="vertical-align:middle;width:35.58%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;"><span style="font-size:9.5pt;">Jerry Schneider (Chairperson)</span></p></td><td style="vertical-align:middle;width:3.69%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;"><span style="font-size:9.5pt;">&#160;</span></p></td><td style="vertical-align:middle;width:31.62%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;"><span style="font-size:9.5pt;">Michael Nagel (Chairperson)</span></p></td></tr><tr><td style="vertical-align:middle;width:25.38%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;"><span style="font-size:9.5pt;">Jerry Schneider</span></p></td><td style="vertical-align:middle;width:3.69%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;"><span style="font-size:9.5pt;">&#160;</span></p></td><td style="vertical-align:middle;width:35.58%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;"><span style="font-size:9.5pt;">Americo Cicchetti</span></p></td><td style="vertical-align:middle;width:3.69%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;"><span style="font-size:9.5pt;">&#160;</span></p></td><td style="vertical-align:middle;width:31.62%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;"><span style="font-size:9.5pt;">Americo Cicchetti</span></p></td></tr><tr><td style="vertical-align:middle;width:25.38%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;"><span style="font-size:9.5pt;">Michael Nagel</span></p></td><td style="vertical-align:middle;width:3.69%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;"><span style="font-size:9.5pt;">&#160;</span></p></td><td style="vertical-align:middle;width:35.58%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;"><span style="font-size:9.5pt;">Pietro Bersani</span></p></td><td style="vertical-align:middle;width:3.69%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;"><span style="font-size:9.5pt;">&#160;</span></p></td><td style="vertical-align:middle;width:31.62%;margin:0pt;padding:0pt 5.4pt 0pt 5.4pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:justify;margin:0pt;"><span style="font-size:9.5pt;">Pietro Bersani</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The members of our Audit Committee after the Committee Restructuring are Pietro Bersani, Jerry Schneider and Michael Nagel. Pietro Bersani serves as chairperson of the Audit Committee. The Board also determined that Mr.&#160;Pietro Bersani and Mr.&#160;Jerry Schneider as &quot;audit committee financial experts,&quot; as defined by Item&#160;407(d)(5)&#160;of Regulation S-K, based on the Board&#8217;s evaluation of their accounting knowledge, qualifications, and experience, and finding that they have appropriate experience or background that results in their financial sophistication in accordance with the additional requirements of the NASDAQ Listing Rules.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The members of our Compensation Committee after the Committee Restructuring are Jerry Schneider, Americo Cicchetti and Pietro Bersani. Jerry Schneider serves as the chairperson of the committee.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The members of our Nominating Committee after the Committee Restructuring are Michael Nagel, Americo Cicchetti and Pietro Bersani. Michael Nagel still serves as the chairperson of the committee.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Committee Charters adopted on June&#160;8, 2020 will be available on the Company&#8217;s website on November&#160;17, 2020.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_4d6a1f89_1ff4_4e0e_9350_a45ed0f4ee1b"></a></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">SIGNATURES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 5.95pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;"><tr><td style="vertical-align:top;width:52.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:top;width:47.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Kiromic BioPharma,&#160;Inc.</p></td></tr><tr><td style="vertical-align:top;width:52.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;">Date: November&#160;17, 2020</p></td><td style="vertical-align:top;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;">By: </p></td><td style="vertical-align:top;width:43.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt;"><i style="font-style:italic;">/s/ Maurizio Chiriva Internati </i></p></td></tr><tr><td style="vertical-align:top;width:52.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:43.37%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">Maurizio Chiriva Internati</p></td></tr><tr><td style="vertical-align:top;width:52.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:3.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:43.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;">Chief Executive Officer</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6.09pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">- 3 -</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border:0;"></div></body></html>
[{"type": "8-K", "sequence": "1", "filename": "krbp-20201117x8k.htm", "description": "8-K", "secsgml_size_bytes": 38690}]
{"company-data": {"conformed-name": "Kiromic Biopharma, Inc.", "cik": "0001792581", "assigned-sic": "2836", "irs-number": "464762913", "state-of-incorporation": "DE", "fiscal-year-end": "1231"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-39619", "film-number": "201321903"}, "business-address": {"street1": "7707 FANNIN ST.", "street2": "SUITE 140", "city": "HOUSTON", "state": "TX", "zip": "77054", "phone": "832-968-4888"}, "mail-address": {"street1": "7707 FANNIN ST.", "street2": "SUITE 140", "city": "HOUSTON", "state": "TX", "zip": "77054"}, "former-company": {"former-conformed-name": "Kiromic, Inc.", "date-changed": "20191029"}}
​
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
FORM
8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
November 17, 2020
KIROMIC BIOPHARMA, INC.
(Exact name of registrant as specified in its charter)
​
​
​
​
​
Delaware
001-39619
46-4762913
(State or other jurisdiction
of incorporation)
​
(Commission
File Number)
​
(IRS Employer
Identification No.)
​
7707 Fannin, Suite 140
Houston
,
TX
,
77054
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code
(
832
)
968-4888
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
​
​
​
​
​
Title of Each Class
Trading Symbol(s)
Name of Each Exchange on Which Registered
Common Stock, $0.001 par value
​
KRBP
​
The Nasdaq Stock Market LLC
​
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
☐
​
​
​
Item 8.01
Other Events.
In an effort to allocate responsibilities more evenly amongst our independent directors, our Board of Directors (the "
Board
") approved a restructuring of the committees, effective as of November 12, 2020 (the "
Committee Restructuring
"). As of the date hereof, the Board has the following three committees: audit committee (the "
Audit Committee
"), compensation committee (the "
Compensation Committee
") and nominating and corporate governance committee (the "
Nominating Committee
"). The membership of the committees after the Committee Restructuring are described below. Each of our committees operates under a written charter (the "
Committee Charters
") adopted by the Board.
In connection with the Committee Restructuring, the Board appointed members to each such committee. The membership of these three standing committees of the Board is as follows:
Audit Committee
Compensation Committee
Nominating Committee
Pietro Bersani (Chairperson)
Jerry Schneider (Chairperson)
Michael Nagel (Chairperson)
Jerry Schneider
Americo Cicchetti
Americo Cicchetti
Michael Nagel
Pietro Bersani
Pietro Bersani
​
The members of our Audit Committee after the Committee Restructuring are Pietro Bersani, Jerry Schneider and Michael Nagel. Pietro Bersani serves as chairperson of the Audit Committee. The Board also determined that Mr. Pietro Bersani and Mr. Jerry Schneider as "audit committee financial experts," as defined by Item 407(d)(5) of Regulation S-K, based on the Board's evaluation of their accounting knowledge, qualifications, and experience, and finding that they have appropriate experience or background that results in their financial sophistication in accordance with the additional requirements of the NASDAQ Listing Rules.
The members of our Compensation Committee after the Committee Restructuring are Jerry Schneider, Americo Cicchetti and Pietro Bersani. Jerry Schneider serves as the chairperson of the committee.
The members of our Nominating Committee after the Committee Restructuring are Michael Nagel, Americo Cicchetti and Pietro Bersani. Michael Nagel still serves as the chairperson of the committee.
The Committee Charters adopted on June 8, 2020 will be available on the Company's website on November 17, 2020.
​
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
​
Kiromic BioPharma, Inc.
Date: November 17, 2020
By:
/s/ Maurizio Chiriva Internati
​
​
Maurizio Chiriva Internati
​
​
Chief Executive Officer
​
​
​
- 3 -